뉴스벤징가
Eli Lilly's Once-Daily Weight Loss Pill Orforglipron Shows Significant Reduction in Heart Disease Risk
· 발표
기사 요약
Eli Lilly says Phase 3 Foundayo (Orforglipron) data show reduced cardiovascular and type 2 diabetes risks in adults with obesity.
기사 원문에서 발췌했어요.
댓글 —
댓글을 불러오고 있어요…